Field report SE-62 / R1 · sheet /strategy

Corporate StrategyFiled from the territory

SELLAS Vaccine Cuts Death Risk 41% as Patent Expiry Starts in 2026

SELLAS's Phase 3 vaccine cut the death risk by 41% in acute myeloid leukemia and sent shares up 156%, but a $150 million raise, patent expiry and China supply risk cloud the path to approval.

Grid
SE-62 / R1
Surveyed
November 18, 2026
Reading
3 min read
Correspondent
Elena Vasquez
Can a Cancer Vaccine Win the Trial but Lose the Patent Race?
Fig. SE-62 / R1Can a Cancer Vaccine Win the Trial but Lose the Patent Race? — spencerbdavis1 / pixabay

Field notes

  1. Phase 3 REGAL median survival reached 24.0 months with GPS versus 14.7 months on best available treatment.
  2. The trial showed a 41% lower risk of death, and SELLAS shares rose 156% in one session.
  3. SELLAS launched a $150 million share offering within hours of the result.
  4. REGAL's p-value was 0.035; the trial was open-label, and the confidence interval and survival curves remained unpublished.
  5. GPS patent expiries begin in 2026; the analysis places the next FDA response in 2027; GenFleet makes every dose.

By Elena Vasquez

SELLAS Life Sciences (Nasdaq: SLS) cut the risk of death by 41% in acute myeloid leukemia, sending its shares up 156% in one session.

In the pivotal Phase 3 REGAL trial, patients in second remission lived a median 24.0 months on galinpepimut-S (GPS), compared with 14.7 months on best available treatment. The 9.3-month difference in median survival delivered the clinical result that few small biotechs achieve.

Within hours of the stock surge, SELLAS launched a $150 million share offering. The sequence placed financing stakes immediately: positive trial data lifted the shares, while the new issue could dilute existing holders, an effect the analysis did not quantify.

The financing left the ownership question unresolved because the analysis gave no share count, offering price or final dilution rate. Investors therefore could not translate the $150 million sale into a percentage dilution figure from the information provided.

UDIS_View, the TradingView author of the analysis, wrote: "For investors, the trial has shifted the debate rather than settled it."

What did the pivotal trial establish?

The analysis explains that GPS uses modified peptides to train the immune system to attack WT1, a protein that many leukemias overproduce. That mechanism made WT1 the immune target, while SELLAS's choice of patients determined whether the vaccine faced low-volume residual disease or advanced solid tumors.

It also notes that earlier WT1 vaccines failed against bulky solid tumors, so SELLAS targeted patients with only residual disease after chemotherapy. The analysis says no approved maintenance therapy exists in this setting.

The design therefore tested GPS after chemotherapy in a population with a small residual tumor burden, not against the bulky tumors that had defeated earlier WT1 vaccines.

What remains uncertain?

The source said key statistics remain unpublished, specifically the confidence interval and survival curves. It also cited a p-value of 0.035 as leaving little margin and noted that REGAL was open-label.

Until those figures appear, investors must assess the 9.3-month median benefit without the full statistical package. The open-label design and p-value leave more room for debate than the 41% headline alone.

Can patents protect GPS?

Several original U.S. patents covering GPS peptides expire from 2026 onward, according to the analysis. It also says Memorial Sloan Kettering owns most of the underlying science.

As a result, FDA exclusivity, rather than patents, would form the real commercial moat after approval. The first patent expiries begin in 2026, ahead of the FDA response the analysis places in 2027.

That chronology leaves SELLAS without a long patent runway at the point of potential approval. Its post-approval protection would depend more on regulatory exclusivity than on the original peptide claims that helped define GPS.

Where does supply-chain exposure sit?

The analysis identifies Shanghai-based GenFleet as the source of SELLAS's second drug, SLS009, and says GenFleet also manufactures every dose.

It also says the BIOSECURE Act is already law, giving that dependence growing geopolitical weight even though SELLAS runs trials in the United States and Europe. The manufacturing location therefore remains a strategic exposure despite the trial geography, and SLS009 links the second program to the same partner.

What must investors watch next?

The source frames three unresolved tests for investors:

  • Regulatory decision: How the FDA responds in 2027. The analysis identifies that response as the next major milestone after the trial.
  • Clinical confirmation: Whether full data, including the confidence interval and survival curves, confirm median survival of 24.0 months versus 14.7 months and a 41% lower risk of death.
  • Shareholder dilution: How much dilution the $150 million offering creates; the analysis provides no final figure.

The 156% stock move quantified the immediate market reaction, but it did not answer any of the three questions. The $150 million transaction addresses financing, while the 2027 regulatory path, missing detailed data and GenFleet concentration remain separate risks.

UDIS_View's closing assessment was: "SELLAS has crossed its clinical hurdle. The regulatory, commercial, and geopolitical hurdles still lie ahead."

SELLAS now has clinical validation and a $150 million offering underway, but not a settled regulatory, patent or supply-chain position.

via tradingview.com (Source)

Share this article:

More from Elena Vasquez

Elena Vasquez

Show full bio

Staff writer covering companies, deals and strategy in corporate strategy and chief-executive leadership at CEO Frontier.

489 articles

Filed under

Adjacent sheets

« Previous articleNext article »

End of sheetSE-62 / R1 · November 18, 2026